Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page presents Utah Medical Products, Inc. (UTMD) filings with the U.S. Securities and Exchange Commission, along with AI-generated highlights to help interpret the disclosures. As a Nasdaq-listed medical device manufacturer, Utah Medical Products files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, among other documents.
In its periodic reports, the company provides detailed discussions of revenues, gross profit, operating income, income before tax and net income, broken out by domestic and outside-the-U.S. sales, direct versus OEM channels, and key product categories such as biopharma pressure monitoring devices, Filshie Clip System devices and blood pressure monitoring kits. Management also describes the impact of foreign currency exchange rates, tariffs, litigation expenses and amortization of identifiable intangible assets on its results.
Current reports on Form 8-K capture specific material events. Recent 8-K filings have included the release of quarterly financial information under Item 2.02 and the appointment of a new director, Kevin Timken, under Item 5.02, along with details of his committee roles, stock option grant and cash board fees. Another 8-K disclosed an increase in the company’s regular quarterly cash dividend under Item 8.01.
Stock Titan’s tools surface these filings as they appear on EDGAR and provide AI-powered summaries that explain the key points in plain language. Users can quickly scan 10-K and 10-Q discussions of segment performance, margins and risk factors, review 8-K announcements about dividends or board changes, and examine exhibits attached to the filings. Form 4 insider transaction reports, proxy statements and other documents, when available, can also be reviewed here to build a fuller picture of Utah Medical Products’ governance, compensation and insider activity.
Utah Medical Products, Inc. furnished an update on its business by providing financial information for the three and twelve months ended December 31, 2025, in a press release dated January 29, 2026. The press release, attached as Exhibit 99.1, also contains forward-looking statements about 2025 and beyond.
The company submitted this information under a current report, stating that the material is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.
Utah Medical Products Inc. director Kevin Timken reported an initial beneficial ownership position that includes a stock option to buy 10,000 shares of the company’s common stock. The option has an exercise price of $58.10 per share, becomes exercisable on 10/01/2026, and expires on 10/31/2035.
The option vests 25% on 10/01/2026, with an additional 6.25% vesting on 01/01/2027 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 10/01/2029. This filing reflects his status as a director and provides transparency into his equity-based compensation.
Utah Medical Products Inc. (UTMD) reported an equity compensation award to its Principal Financial Officer. On 10/31/2025, the officer received an employee stock option to buy 500 shares of UTMD common stock at an exercise price of $58.1 per share. The option expires on 10/31/2035 and will vest 25% on 1/1/27, with an additional 6.25% vesting on 4/1/27 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 1/1/30. Following this grant, the officer beneficially owned 5,600 derivative securities directly.
Utah Medical Products (UTMD) filed its Q3 2025 report showing sales of $9.812M and diluted EPS of $0.82. Gross margin was 57.1% and operating margin 26.6%, both lower year over year as operating income fell 21.9%.
Management cited two outside‑U.S. distributor cancellations/delays that reduced shipments by $976 and revenues by $581, and recorded a $395 bad‑debt reserve tied to a China distributor fee. Non‑operating income eased with lower cash yields. By category, Q3 sales were Gynecology/Electrosurgery/Urology $4.954M (down), Neonatal $2.176M (up), Blood Pressure Monitoring $1.643M (down), and Labor & Delivery $1.039M (flat).
Year to date, sales were $29.475M and EPS $2.68. Cash and investments were $84.267M, current liabilities $3.011M. The company repurchased 130,984 shares for $7.361M and paid $3.006M in dividends. Management now expects 2025 revenue to be 6–7% lower than 2024 and EPS of $3.40–$3.50.
Utah Medical Products (UTMD) expanded its Board from five to six members and appointed Kevin Timken as a director. He will serve on the Audit Committee and the Compensation and Benefits Committee. Timken previously advised UTMD on U.S. SEC matters during a 25-year legal career.
As a director, Timken received 10,000 stock options with an exercise price of $58.10 per share, vesting over four years, and the standard Board fee of $7,650 per quarter, pro‑rated for the final quarter of 2025.
UTMD also increased its regular quarterly cash dividend to $0.31 per share, payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025.
Utah Medical Products, Inc. furnished an update on its results under Item 2.02. The company attached a press release (Exhibit 99.1) with financial information for the three and nine months ended September 30, 2025, along with forward-looking statements for 2025 and beyond.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings.
Brandes Investment Partners, L.P. filed an amendment to Schedule 13G reporting beneficial ownership of 333,204 common shares of Utah Medical Products Inc (UTMD), representing 10.39% of the class. The filing shows Brandes has shared voting power over 286,784 shares and shared dispositive power over 333,204 shares, with no sole voting or dispositive power. The form states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing identifies the reporting person as an investment adviser organized in Delaware and lists principal office at 4275 Executive Square, La Jolla, CA. The signature on the amendment is dated 09/02/2025.
Brian L. Koopman, Principal Financial Officer of Utah Medical Products Inc. (UTMD), reported the sale of 50 shares of the company's common stock on 09/04/2025 at a price of $62.75 per share. Following the reported transaction, Mr. Koopman beneficially owns 832 shares in a direct capacity. The Form 4 is signed by Mr. Koopman on 09/05/2025.
Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.
Brandes Investment Partners, L.P. reports beneficial ownership of 271,537 common shares of Utah Medical Products, representing 7.39% of the class as stated in Item 4. The filing shows Brandes holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, indicating it does not exercise unilateral control.
The statement is filed on Schedule 13G/A and classifies the reporting person as IA, PN (investment adviser/portfolio manager). The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Utah Med Prods (UTMD)?
What is the market cap of Utah Med Prods (UTMD)?
